0000950170-23-027063.txt : 20230608
0000950170-23-027063.hdr.sgml : 20230608
20230608171058
ACCESSION NUMBER: 0000950170-23-027063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230606
FILED AS OF DATE: 20230608
DATE AS OF CHANGE: 20230608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Michaelson Jennifer
CENTRAL INDEX KEY: 0001838061
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 231002885
MAIL ADDRESS:
STREET 1: C/O CULLINAN MANAGEMENT, INC.
STREET 2: ONE MAIN STREET SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Oncology, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
ownership.xml
4
X0407
4
2023-06-06
0001789972
Cullinan Oncology, Inc.
CGEM
0001838061
Michaelson Jennifer
C/O CULLINAN ONCOLOGY, INC.
ONE MAIN STREET, SUITE 1350
CAMBRIDGE
MA
02142
false
true
false
false
Chief Development Officer
true
Common Stock
2023-06-06
4
M
false
11900
4.30
A
102347
D
Common Stock
2023-06-06
4
S
false
11900
12.31
D
90447
D
Common Stock
2023-06-07
4
M
false
100
4.30
A
90547
D
Common Stock
2023-06-07
4
S
false
100
12.40
D
90447
D
Stock Option (Right to Buy)
4.30
2023-06-06
4
M
false
11900
0
D
2030-10-28
Common Stock
11900
188693
D
Stock Option (Right to Buy)
4.30
2023-06-07
4
M
false
100
0
D
2030-10-28
Common Stock
100
188593
D
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.30 to $12.35. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
/s/ Jacquelyn Sumer, Attorney-in-Fact
2023-06-08